Generation Bio
In vivo gene therapy using a proprietary platform to deliver genetic material to target tissues
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2016
- Latest Form D
- $111M, Jan 2020
- Total capital
- $212M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $212M
- 2 Form D · last Jan 2020
- 81 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 29 pending · first 2025
- Rank in peer group#156 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$111M
- Private capital raisedForm D · SEC · 1st filing$100M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#156 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anthony QuinnDirectorNamed in SEC Form D filings
- Catherine Stehman-BreenDirectorNamed in SEC Form D filings
- Charlie RowlandDirectorNamed in SEC Form D filings
- Donald NicholsonDirectorNamed in SEC Form D filings
- Geoff McDonoughyExecutive Officer, DirectorNamed in SEC Form D filings
- Geoffrey McDonoughExecutive Officer, DirectorNamed in SEC Form D filings
Show all 12 people
- Glenn GoddardExecutive OfficerNamed in SEC Form D filings
- Gustav ChristensenDirectorNamed in SEC Form D filings
- Jason RhodesDirectorNamed in SEC Form D filings
- Jeff JonasDirectorNamed in SEC Form D filings
- Mark AngelinoExecutive OfficerNamed in SEC Form D filings
- Thomas GraneyExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 40- New patentStealth Lipid Nanoparticle Compositions For Cell TargetingUSPTOUS 12,746,209
- GrantedLipids And Compositions ThereofUSPTOUS 12,734,249
- GrantedCompositions And Production Of Nicked Closed-ended Dna VectorsUSPTOUS 12,729,386
Show all 40 patent records
- Stealth Lipid Nanoparticle Compositions For Cell TargetingSep 29, 2026 · US 12,746,209Granted
- Lipids And Compositions ThereofSep 15, 2026 · US 12,734,249Granted
- Compositions And Production Of Nicked Closed-ended Dna VectorsSep 8, 2026 · US 12,729,386Granted
- Stealth Lipid Nanoparticle Compositions For Cell TargetingJun 25, 2026 · Application 19061085Pending
- Bispecific Stealth Lipid Nanoparticle Compositions For Cell TargetingApr 23, 2026 · Application 19327048Pending
- Synthetic Production Of Single-stranded Adeno Associated Viral Dna VectorsMar 17, 2026 · US 12,577,573Granted
- CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOFFeb 26, 2026 · Application 19104655Pending
- Polyglycerol-conjugated Lipids And Lipid Nanoparticle Compositions Comprising The SameFeb 12, 2026 · Application 19238030Pending
- Stealth Lipid Nanoparticle Compositions For Cell TargetingFeb 12, 2026 · Application 19058352Pending
- Novel Lipids And Nanoparticle Compositions ThereofJan 27, 2026 · US 12,534,435Granted
- Lipids And Nanoparticle Compositions ThereofNov 27, 2025 · Application 19042351Pending
- Lipid Nanoparticle Compositions And Uses ThereofNov 20, 2025 · Application 18871840Pending
- Bispecific Stealth Lipid Nanoparticle Compositions For Cell TargetingOct 28, 2025 · US 12,453,706Granted
- Closed-ended Dna Vectors Obtainable From Cell-free Synthesis And Process For Obtaining Cedna VectorsOct 14, 2025 · US 12,442,015Granted
- Non-viral Dna Vectors And Uses Thereof For Expressing Phenylalanine Hydroxylase (pah) TherapeuticsSep 16, 2025 · US 12,415,002Granted
- Stealth Lipid Nanoparticle Compositions For Cell TargetingSep 11, 2025 · Application 19063950Pending
- Non-viral Dna Vectors And Uses Thereof For Expressing Fviii TherapeuticsSep 11, 2025 · Application 19214171Pending
- Lipids And Compositions ThereofAug 7, 2025 · Application 19063444Pending
- Non-viral Dna Vectors And Uses Thereof For Expressing Fviii TherapeuticsJun 24, 2025 · US 12,338,275Granted
- Lipids And Compositions ThereofApr 1, 2025 · US 12,263,228Granted
- Novel Lipids And Nanoparticle Compositions ThereofMar 18, 2025 · US 12,252,470Granted
- Scalable And High-purity Cell-free Synthesis Of Closed-ended Dna VectorsFeb 13, 2025 · Application 18722701Pending
- Liver-specific Expression Cassettes, Vectors And Uses Thereof For Expressing Therapeutic ProteinsDec 5, 2024 · Application 18690020Pending
- Single Chain Variable Fragment (scfv) Modified Lipid Nanoparticle Compositions And Uses ThereofNov 21, 2024 · Application 18578073Pending
- Cationic Lipids And Compositions ThereofSep 5, 2024 · Application 18569623Pending
- Non-viral Dna Vectors For Vaccine DeliveryAug 22, 2024 · Application 18289622Pending
- Lyophilized Non-viral Dna Vector Compositions And Uses ThereofAug 8, 2024 · Application 18289625Pending
- Non-viral Dna Vectors Expressing Therapeutic Antibodies And Uses ThereofJul 11, 2024 · Application 18288669Pending
- Non-viral Dna Vectors And Uses Thereof For Expressing Pfic TherapeuticsJun 6, 2024 · Application 18282717Pending
- Closed-ended Dna Vectors And Uses Thereof For Expressing Phenylalanine Hydroxylase (pah)Jan 25, 2024 · Application 18025926Pending
- Non-viral Dna Vectors And Uses Thereof For Expressing Fviii TherapeuticsNov 30, 2023 · Application 18026377Pending
- Methods For Encapsulating Polynucleotides Into Reduced Sizes Of Lipid Nanoparticles And Novel Formulation ThereofOct 12, 2023 · Application 18015575Pending
- Novel Lipids And Nanoparticle Compositions ThereofJun 15, 2023 · Application 17925404Pending
- Non-viral Dna Vectors And Uses Thereof For Expressing Factor Ix TherapeuticsMay 4, 2023 · Application 17913477Pending
- Non-viral Dna Vectors And Uses Thereof For Expressing Gaucher TherapeuticsMay 4, 2023 · Application 17913482Pending
- Ionizable Lipids And Nanoparticle Compositions ThereofNov 24, 2022 · Application 17642314Pending
- Gene Editing Using A Modified Closed-ended Dna (cedna)Sep 15, 2022 · Application 16769671Pending
- Methods And Compositions For Reducing Gene Or Nucleic Acid Therapy-related Immune ResponsesSep 15, 2022 · Application 17617336Pending
- Lipid Nanoparticle Compositions Comprising Closed-ended Dna And Cleavable Lipids And Methods Of Use ThereofSep 8, 2022 · Application 17632262Pending
- Closed-ended Dna (cedna) And Immune Modulating CompoundsJun 16, 2022 · Application 17435419Pending
Related companies, and why
- Cyclerion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Endeavor BioMedicinesSimilar federal contract value in Biotech · null in contracts
- AbsciSimilar federal contract value in Biotech · null in contracts
- Renibus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Candid TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Revolution MedicinesSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .